Evidence map›Paper›PMID 41045229›Full record

ReviewESC heart failure2025

Worsening versus advanced heart failure: Management and challenges.

Alberto Palazzuoli, Marco Giuseppe Del Buono, Giulia La Vecchia, Stephen J Greene, Andrew P Ambrosy, Ovidiu Chioncel, Finn Gustafsson, Selim R Krim, Carl J Lavie, Marianna Adamo and 6 more

Abstract readReview
In one paragraph

Review in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Alberto PalazzuoliCardiovascular Diseases Unit, Cardio-Thoracic and Vascular Department, Le Scotte Hospital, University of Siena, Siena, Italy.
Marco Giuseppe Del BuonoDepartment of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Giulia La VecchiaDepartment of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.
Stephen J GreeneDuke Clinical Research Institute, Durham, North Carolina, USA.
Andrew P AmbrosyDepartment of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.
Ovidiu ChioncelInstitute of Cardiovascular Diseases 'Prof. CC Iliescu', University of Medicine, Bucharest, Romania.
Finn GustafssonDepartment of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Selim R KrimSection of Cardiomyopathy & Heart Transplantation, John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, New Orleans, Louisiana, USA.
Carl J LavieJohn Ochsner Heart and Vascular Institute Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, Louisiana, USA.
Marianna AdamoDepartment of Cardiology, Civil Hospital of Brescia, University of Brescia, Brescia, Italy.
Tuvia Ben GalHeart Failure Unit, Cardiology Department, Rabin Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Oliviana GeavleteInstitute of Cardiovascular Diseases 'Prof. CC Iliescu', University of Medicine, Bucharest, Romania.
Laura AntohiInstitute of Cardiovascular Diseases 'Prof. CC Iliescu', University of Medicine, Bucharest, Romania.
Giuseppe RosanoDepartment of Human Sciences and Promotion of Quality of Life, San Raffaele Open University of Rome, Rome, Italy.
Sean CollinsDepartment of Emergency Medicine and Veterans Affairs Tennessee Valley Healthcare System, Geriatric Research, Education and Clinical Center (GRECC), Nashville, Tennessee, USA.
Filippo CreaDepartment of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is a progressive condition marked by recurrent episodes of symptom exacerbation, leading to worsening cardiac function, increased hospitalization and mortality risk. Worsening HF (WHF) and advanced HF (AdvHF) represent two distinct stages in this progression, each with unique clinical features and therapeutic needs. WHF is characterized by a deterioration of pre-existing symptoms requiring intensified treatment, such as diuretic escalation, which often reflects disease progression. Conversely, AdvHF involves severe cardiac dysfunction with persistent symptoms despite optimal medical management, requiring advanced interventions such as inotropic support or heart transplant. Although both stages share some pathophysiological and clinical features, they differ significantly in haemodynamic profiles, disease severity and response to treatment. This review argues that recognizing the transition from WHF to AdvHF is a pivotal issue in patient care. We explore the distinct natural histories, clinical presentations and diagnostic markers of WHF and AdvHF to provide a framework for earlier, more targeted interventions aimed at altering the disease trajectory and preventing the decline associated with the advanced stage. While WHF symptoms are typically reversible with appropriate interventions, AdvHF represents the end stage of HF with often irreversible dysfunction and multi-organ involvement. A clearer understanding and standardized definition of these phenotypes are essential for improving patient outcomes and guiding future clinical research.

Indexed as

Disease ManagementHeart FailureDisease ProgressionHumansSeverity of Illness Indexadvanced heart failurehospitalizationmanagementoutcomeworsening heart failure

Identifiers

PMID41045229
PMCPMC12719834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.